Brian K Law

Brian K Law, Ph.D.

Associate Professor

Department: MD-PHARMACOLOGY / THERAPEUTICS
Business Phone: (352) 273-9423
Business Email: bklaw@ufl.edu

Teaching Profile

Courses Taught
2019-2021
GMS6551 Fundamentals of Medical Pharmacology and Therapeutics
2019-2025
GMS6540 Medical Pharmacology and Therapeutics IV: Cancer, Antimicrobial and Antiparasitic Agents
2019-2021
GMS6520 Medical Pharmacology and Therapeutics I: The Nervous System
2019-2021
GMS6531 Medical Pharmacology and Therapeutics III: Endocrine, Musculoskeletal and Reproductive Systems
2018-2021,2023-2025
GMS6560 Molecules to Man: Past, Present and Future Therapeutic Strategies for Disease
2019-2021
GMS6530 Medical Pharmacology and Therapeutics II: Cardiovascular, Renal and Respiratory Systems
2020-2023
PAS5026 Pharmacotherapeu 2
2013-2014,2016-2023
GMS6001 Fundamentals of Biomedical Sciences I
2016-2023
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2020-2025
GMS6691 Special Topics in Cell Biology and Anatomy
2011-2013,2015-2025
GMS6009 Principles of Drug Action and Therapeutics
2011-2025
DEN6262 Prin of Pharmacology
2014-2015,2017-2025
GMS6065 Fundamentals of Cancer Biology
2016-2018,2020-2024
GMS6064 Tumor Biology
2018
GMS7980 Research for Doctoral Dissertation
2018
CHM7979 Advanced Research
2018
GMS7979 Advanced Research
2015,2018-2024,2024
BMS6638C Kidney & Urinary Tract
2018,2024-2025
BMS6300 Fund Micro and Immuno
2013,2015-2017
GMS6051 Signal Transduction
2014,2016-2022,2022
MDU4002 Introduction to Medical Science Seminar 2
2016
GMS6644 Apoptosis
2013-2014,2023
BMS6031 Foundations of Med
2021
GMS6552 Cell Signaling & Therapeutics
2021
GMS6504 Advanced Medical Pharmacology
2024-2025
BMS6633 The Cv System
Teaching Philosophy
TEACHING PHILOSOPHY STATEMENT Brian K. Law, Ph.D. A mind is a fire to be kindled, not a vessel to be filled. -Plutarch The purpose of a science course is to teach fundamental scientific principles and to bring the student to the realization that the application of basic scientific principles, when used according to the scientific method, allows the scientist to investigate any research problem in a logical and productive manner. The responsibilities of the teacher are several-fold. The teacher should present the empirical data that led to the formulation of individual principles so that the student realizes that scientific laws are not abstract principles, but rather have their basis in the very properties of nature itself. Once the student has grasped the fundamental principles, the teacher must demonstrate how these ideas can be used to pose and answer new and significant questions using the scientific method. As a teacher I use all the tools at my disposal to insure that each student has every opportunity to develop a strong foundation in scientific knowledge and its applications to allow the student to achieve his or her career goals. Lectures will be designed using a large number of examples and demonstrations such that the students themselves will come to the same conclusions reached by the great scientists of the past. Laboratory classes will be used to reinforce the lectures, as well as to give the students exposure to the science and the art of experimental design. I will hold flexible office hours so that students will be able to ask any questions or address any concerns. Office hours and “help sessions” will also allow me to determine which material proves particularly difficult to the students and should be covered more thoroughly in the lecture and laboratory classes. Students in graduate, undergraduate, and professional courses will be thoroughly exposed to the current literature in order to develop critical thinking skills. Critical thinking skills will be developed by critiquing journal articles in terms of (1) the significance or relevance of the scientific question addressed in the article, (2) the appropriateness of the experimental methods and controls used by the authors, (3) whether or not the experimental results obtained support the conclusions reached by the authors, and (4) whether alternate conclusions could be reached from the same experimental results. Since communication skills are critical to the success of future scientists, learners will be asked to present journal articles or solve problems in a team-based format in front of their peers and be critiqued by their peers. These experiences will demonstrate to the student in a dramatic way what makes up an effective presentation and how they can improve their communication and critical thinking skills. As a teacher at UF I have had the opportunity to instruct and guide a wide array of learners including medical students, dental students, graduate (Ph.D. and M.S.) students, and undergraduate research volunteers. If am familiar with multiple teaching modalities including didactic lecturing, flipped-classroom, and team-based learning approaches. I feel that these experiences have given me a wide array of educational skills that can be brought to bear in the classroom.

Research Profile

Some of the Law Lab’s primary research interests revolves around cyclin-dependent kinases (Cdks) in mammary tumorigenesis and chromosomal instability, and Cdk regulation by the mTOR and TGFβ pathways. This research involves the use of novel models to understand how the activation of Cdks in the mammary gland causes tumor formation by dysregulation of cell proliferation and through genetic alterations that result from chromosomal instability. These models also provide systems for testing new therapeutic strategies, including non-ATP competitive Cdk inhibitors discovered in their laboratory and for targeting the upstream signaling pathways, such as the mTOR and TGFβ axes, that stimulate Cdk kinase activity.

Other Areas of Interest

Mechanisms by which CDCP1 Promotes Breast Cancer Metastasis: The CDCP1 protein functions as a scaffold to bring together and facilitate synergy between the oncoproteins Epidermal Growth Factor Receptor (EGFR) and the Src tyrosine kinase. This results in disassembly of cell-cell and cell-substratum adhesion complexes and may facilitate cancer metastasis by permitting cancer cell invasion and de-adhesion. Current work is directed toward identifying pharmacological strategies to block the pro-metastatic functions of CDCP1. (Law, M., et al. Oncogene (2013) 32:1316; Law, M., et al. Breast Cancer Research (2016) 18:80)

Activation of Death Receptors 4 and 5 by Altered Disulfide Bonding as a New Approach to Cancer Therapy: Our collaborative team identified a novel class of anticancer agents termed Disulfide bond Disrupting Agents (DDAs). DDAs selectively kill cancer cells that overproduce the oncoproteins Epidermal Growth Factor Receptor (EGFR/HER1), the EGFR family member, HER2, or the transcription factor MYC. DDA-induced cell death is mediated by the Death Receptors DR4 and DR5, which activate the Caspase 8-Caspase 3 pro-apoptotic cascade. Current work focuses on elucidating the molecular mechanisms by which DDAs activate DR4/5. (Wang, M., et al. Cell Death Discovery (2019) 5:153; Wang, M., et al., Oncogene (2019) 38:4264)   Identification of the First Active Site Inhibitors of the Disulfide Isomerases ERp44 and AGR2 as Novel Anticancer Agents: Affinity-tagged DDA molecules were used to identify the Protein Disulfide Isomerases ERp44, AGR2/3, and PDIA1 as the direct DDA target proteins in cancer cells that mediate DDA actions. Ongoing efforts are focused on understanding the structural features of the DDAs and their target proteins that control DDA target selectivity, and on determining the role of the DDA target enzymes in regulating the disulfide bonding patterns of their client proteins, Death Receptors 4 and 5, and the HER-family receptor tyrosine kinases EGFR and HER2. (Law, M., et al. bioRxiv preprint doi: https://doi.org/10.1101/2021.01.13.426390)

Areas of Interest
  • Cancer
  • Cell Cycle Regulation
  • Drug discovery
Open Researcher and Contributor ID (ORCID)

0000-0002-8411-6531

Publications

2024
DR5 disulfide bonding as a sensor and effector of protein folding stress.
bioRxiv : the preprint server for biology. [DOI] 10.1101/2024.03.04.583390. [PMID] 38496520.
2023
The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer.
Cell communication and signaling : CCS. 21(1) [DOI] 10.1186/s12964-023-01182-5. [PMID] 37430297.
2023
Who Knew? Dopamine Transporter Activity Is Critical in Innate and Adaptive Immune Responses
Cells. 12(2) [DOI] 10.3390/cells12020269. [PMID] 36672204.
2022
Anticancer Agents Derived from Cyclic Thiosulfonates: Structure‐Reactivity and Structure‐Activity Relationships
ChemMedChem. 17(14) [DOI] 10.1002/cmdc.202200165. [PMID] 35491396.
2022
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(4):756-769 [DOI] 10.1158/1078-0432.CCR-21-2863. [PMID] 34716195.
2022
Epithelial–Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress
Cells. 11(14) [DOI] 10.3390/cells11142208. [PMID] 35883651.
2022
Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
Cancer letters. 534 [DOI] 10.1016/j.canlet.2022.215604. [PMID] 35247515.
2022
Retraction: αB-Crystallin, an Effector of Unfolded Protein Response, Confers Anti-VEGF Resistance to Breast Cancer via Maintenance of Intracrine VEGF in Endothelial Cells.
Molecular cancer research : MCR. 20(7) [DOI] 10.1158/1541-7786.MCR-22-0454. [PMID] 35791691.
2022
Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A
iScience. 25(7) [DOI] 10.1016/j.isci.2022.104518. [PMID] 35754740.
2021
Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm
Current Research in Pharmacology and Drug Discovery. 2 [DOI] 10.1016/j.crphar.2021.100053. [PMID] 34909679.
2021
Repurposing Tranexamic Acid as an Anticancer Agent.
Frontiers in pharmacology. 12 [DOI] 10.3389/fphar.2021.792600. [PMID] 35095503.
2019
A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
Haematologica. 104(9):e415-e419 [DOI] 10.3324/haematol.2018.207704. [PMID] 30792209.
2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers
Oncogene. 38(22):4264-4282 [DOI] 10.1038/s41388-019-0717-6.
2019
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
European journal of medicinal chemistry. 161:456-467 [DOI] 10.1016/j.ejmech.2018.10.052. [PMID] 30384048.
2019
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway
Cell Death Discovery. 5(1) [DOI] 10.1038/s41420-019-0228-9. [PMID] 31839995.
2018
Loss of sirtuin 1 and mitofusin 2 contributes to enhanced ischemia/reperfusion injury in aged livers.
Aging cell. 17(4) [DOI] 10.1111/acel.12761. [PMID] 29774638.
2018
The unfolded protein response as a target for anticancer therapeutics.
Critical reviews in oncology/hematology. 127:66-79 [DOI] 10.1016/j.critrevonc.2018.05.003. [PMID] 29891114.
2017
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Oncotarget. 8(17):28971-28989 [DOI] 10.18632/oncotarget.15952. [PMID] 28423644.
2017
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.
Journal of natural products. 80(11):2969-2986 [DOI] 10.1021/acs.jnatprod.7b00551. [PMID] 29087712.
2017
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer.
Marine drugs. 15(9) [DOI] 10.3390/md15090290. [PMID] 28926939.
2017
NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.
Oncotarget. 8(34):57246-57264 [DOI] 10.18632/oncotarget.19778. [PMID] 28915668.
2016
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.
Breast cancer research : BCR. 18(1) [DOI] 10.1186/s13058-016-0741-1. [PMID] 27495374.
2016
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.
The Journal of clinical investigation. 126(11):4174-4186 [DOI] 10.1172/JCI86623. [PMID] 27721239.
2016
Interaction between APC and Fen1 during breast carcinogenesis.
DNA repair. 41:54-62 [DOI] 10.1016/j.dnarep.2016.04.003. [PMID] 27088617.
2016
Sirtuin 1 suppresses mitochondrial dysfunction of ischemic mouse livers in a mitofusin 2-dependent manner.
Cell death and differentiation. 23(2):279-90 [DOI] 10.1038/cdd.2015.96. [PMID] 26184910.
2015
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Molecular pharmacology. 88(5):846-52 [DOI] 10.1124/mol.115.099325. [PMID] 26018905.
2015
Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Oncotarget. 6(12):10445-59 [PMID] 25865227.
2015
NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells.
PloS one. 10(5) [DOI] 10.1371/journal.pone.0123808. [PMID] 25933036.
2015
Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury.
Advances in wound care. 4(6):321-328 [PMID] 26029482.
2015
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Cancer letters. 360(1):60-7 [DOI] 10.1016/j.canlet.2015.02.005. [PMID] 25676691.
2014
A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors.
Autophagy. 10(11):2021-35 [DOI] 10.4161/auto.32229. [PMID] 25483883.
2014
SERPINE1: A Molecular Switch in the Proliferation-Migration Dichotomy in Wound-“Activated” Keratinocytes.
Advances in wound care. 3(3):281-290 [PMID] 24669362.
2014
Signaling mechanisms that suppress the cytostatic actions of rapamycin.
PloS one. 9(6) [DOI] 10.1371/journal.pone.0099927. [PMID] 24927123.
2014
The basic helix-loop-helix/leucine zipper transcription factor USF2 integrates serum-induced PAI-1 expression and keratinocyte growth.
Journal of cellular biochemistry. 115(10):1840-7 [DOI] 10.1002/jcb.24861. [PMID] 24905330.
2013
Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes.
Biochemistry. 52(20):3489-501 [DOI] 10.1021/bi400047u. [PMID] 23627734.
2013
Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints.
Journal of cell science. 126(Pt 5):1207-17 [DOI] 10.1242/jcs.117382. [PMID] 23321641.
2013
Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development.
Cancer letters. 332(1):120-9 [DOI] 10.1016/j.canlet.2012.11.016. [PMID] 23196055.
2013
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Oncogene. 32(10):1316-29 [DOI] 10.1038/onc.2012.138. [PMID] 22543582.
2013
Small-Molecule Inhibitors of Acetyltransferase P300 Identified By High-Throughput Screening Are Potent Anticancer Agents (Vol 12, Pg 610, 2013)
Molecular Cancer Therapeutics. 12(8):1688-1688 [DOI] 10.1158/1535-7163.MCT-13-0441.
2013
Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Molecular cancer therapeutics. 12(5):610-20 [DOI] 10.1158/1535-7163.MCT-12-0930. [PMID] 23625935.
2013
The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition.
The Journal of biological chemistry. 288(38):27680-27691 [DOI] 10.1074/jbc.M113.482349. [PMID] 23928305.
2012
An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.
Cancer letters. 326(2):183-90 [DOI] 10.1016/j.canlet.2012.08.013. [PMID] 22906417.
2012
TGF-beta antiproliferative effects in tumor suppression.
Frontiers in bioscience (Scholar edition). 4(2):749-66 [PMID] 22202088.
2011
In pursuit of new anti-angiogenic therapies for cancer treatment.
Frontiers in bioscience (Landmark edition). 16(3):803-14 [PMID] 21196204.
2011
αB-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells.
Molecular cancer research : MCR. 9(12):1632-43 [DOI] 10.1158/1541-7786.MCR-11-0327. [PMID] 21984182.
2010
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
The Journal of pharmacology and experimental therapeutics. 335(2):351-61 [DOI] 10.1124/jpet.110.172387. [PMID] 20739454.
2010
Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-kappaB using in silico molecular docking.
Cancer letters. 291(2):217-24 [DOI] 10.1016/j.canlet.2009.10.015. [PMID] 19910110.
2010
Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition.
Oncogene. 29(35):4896-904 [DOI] 10.1038/onc.2010.234. [PMID] 20562920.
2010
The B56gamma3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition.
The Journal of biological chemistry. 285(28):21567-80 [DOI] 10.1074/jbc.M109.094953. [PMID] 20448040.
2009
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
The Journal of biological chemistry. 284(43):29945-55 [DOI] 10.1074/jbc.M109.055251. [PMID] 19710018.
2009
Amino acid Asp181 of 5′-flap endonuclease 1 is a useful target for chemotherapeutic development.
Biochemistry. 48(42):9952-8 [DOI] 10.1021/bi9010754. [PMID] 19769410.
2009
Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation.
Molecular pharmacology. 76(1):91-104 [DOI] 10.1124/mol.109.056085. [PMID] 19403701.
2009
Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest.
Differentiation; research in biological diversity. 78(1):35-44 [DOI] 10.1016/j.diff.2009.04.001. [PMID] 19427096.
2009
Identification of Compounds That Enhance and Suppress Autophagy
Autophagy. 5:910-911
2009
Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-kappaB.
Cancer letters. 275(1):139-49 [DOI] 10.1016/j.canlet.2008.10.007. [PMID] 19038492.
2008
Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1.
Journal of cellular biochemistry. 105(2):596-611 [DOI] 10.1002/jcb.21860. [PMID] 18729074.
2008
Lessons from the first comprehensive molecular characterization of cell cycle control in rodent insulinoma cell lines.
Diabetes. 57(11):3056-68 [DOI] 10.2337/db08-0393. [PMID] 18650366.
2008
Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.
Neoplasia (New York, N.Y.). 10(11):1240-52 [PMID] 18953433.
2008
Tumors Initiated By Constitutive Cdk2 Activation Contain An Invasive Basal Component
Virchows Archiv. 452:S147-S148
2007
Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway.
Oncogene. 26(41):6021-30 [PMID] 17384681.
2007
Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
Cancer research. 67(7):3135-44 [PMID] 17409420.
2006
Cellular Mechanism Through Which Parathyroid Hormone-Related Protein Induces Proliferation in Arterial Smooth Muscle Cells
. 99:933-942
2006
Metaplastic carcinoma of the breast: a clinicopathological review.
Journal of clinical pathology. 59(10):1079-83 [PMID] 16467167.
2006
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Cancer research. 66(2):1070-80 [PMID] 16424043.
2006
Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.
The Journal of biological chemistry. 281(45):33971-81 [PMID] 16959768.
2005
Rapamycin: an anti-cancer immunosuppressant?
Critical reviews in oncology/hematology. 56(1):47-60 [PMID] 16039868.
2005
Signaling Cross-talk between Insulin-like Growth Factor Binding Protein-3 (IGFBP3) and Transforming Growth Factor-ß (TGFß)
Journal of Molecular Endocrinology. 34:723-737
2004
Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro.
Neoplasia (New York, N.Y.). 6(5):603-10 [PMID] 15548370.
2004
Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein.
Breast cancer research : BCR. 6(2):R130-9 [PMID] 14979923.
2003
Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2A(C), PP4(C), and PP6(C)) and analysis of the interaction of PP2A(C) with alpha4 protein.
Protein expression and purification. 31(1):19-33 [PMID] 12963337.
2003
Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line.
Breast cancer research : BCR. 5(6):R187-98 [PMID] 14580254.
2002
Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.
Molecular and cellular biology. 22(23):8184-98 [PMID] 12417722.
2001
Antagonistic effects of TGFbeta1 and BMP-6 on skin keratinocyte differentiation.
Experimental cell research. 263(2):265-73 [PMID] 11161725.
2001
Induction of the C/EBP homologous protein (CHOP) by amino acid deprivation requires insulin-like growth factor I, phosphatidylinositol 3-kinase, and mammalian target of rapamycin signaling.
Endocrinology. 142(1):221-8 [PMID] 11145585.
2000
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen.
The Journal of biological chemistry. 275(49):38261-7 [PMID] 10993886.
1999
Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation.
Annals of the New York Academy of Sciences. 886:265-8 [PMID] 10667235.
1999
Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway.
The Journal of biological chemistry. 274(8):4743-8 [PMID] 9988711.
1999
Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription.
The Journal of biological chemistry. 274(52):37413-20 [PMID] 10601313.
Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death
. [DOI] 10.1101/2021.01.13.426390.
Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator
. [DOI] 10.1101/700906.

Grants

Jul 2023 ACTIVE
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jun 2023 ACTIVE
Reducing racial disparity in breast cancer survival with a novel synthetic-lethal strategy
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
May 2023 – Mar 2024
Optimizing novel small molecule activators of Death Receptor 5 for breast cancer therapy
Role: Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Jul 2022 – Jun 2024
Novel Breast Cancer Therapeutics Targeting a Unique Subset of Disulfide Isomerases
Role: Principal Investigator
Funding: FL BREAST CANCER FOU
Apr 2022 – Mar 2023
Toward IND-Enabling Studies for Novel Cancer Therapeutics that Inhibit the Disulfide Isomerases ERp44, PDIA1, and AGR2
Role: Principal Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jul 2020 – Jun 2023
Regulation of Death Receptor 5 folding and apoptotic signaling by AGR2
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2020 – Jun 2022
Tranexamic Class Antagonists (TXCAs)
Role: Co-Project Director/Principal Investigator
Funding: TRANEXAMIC TECHNOLOGIES
Aug 2019 – Dec 2022
Tranexamic Acid Activity Against Melanoma and Breast Cancer
Role: Principal Investigator
Funding: TRANEXAMIC TECHNOLOGIES
Jul 2019 – Dec 2020
Dual mechanisms of DDA antitumor activity: Induction of tumor cell apoptosis and vascular disruption
Role: Principal Investigator
Funding: FL BREAST CANCER FOU
Jul 2018 – Dec 2020
A new approach for eradicating metastatic, drug-resistant breast cancers
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Feb 2018 – May 2019
Synthetic lethal strategy for killing EGFR+/HER2+ cancers
Role: Principal Investigator
Funding: FL BREAST CANCER FOU
Jul 2015 – Jun 2024
Florida Academic Cancer Center Alliance Seed Grants
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Jun 2015 – Sep 2019
Novel agents that simultaneously downregulate Her2, EGFR, and Her3
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Feb 2015 – Oct 2023
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Feb 2015 – Jan 2016
CDCP1 as a therapeutic target in the dissemination of a
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2014 – Jun 2021
Martens-Maren Chair Fund
Role: Project Manager
Funding: **UF FOU UNRESTRICTED DONATION
Dec 2013 – Nov 2015
Chemistry and Biology of Apratoxins
Role: Project Manager
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Oct 2013 – Oct 2016
Nuovo Biologics Testing
Role: Principal Investigator
Funding: NUOVO BIOLOGICS
Mar 2013 – Aug 2019
Novel Targeted Anticancer Agents from Marine Cyanobacteria
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Jul 2006 – Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS

Contact Details

Phones:
Business:
(352) 273-9423
Emails:
Business:
bklaw@ufl.edu
Addresses:
Business Mailing:
PO Box 100267
GAINESVILLE FL 32610
Business Street:
1200 NEWELL DRIVE
GAINESVILLE FL 32610